Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance

Alfredo Tartarone; Rosa Lerose

doi:10.1177/1753465815587820

Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance

Alfredo Tartarone, Rosa Lerose

IRCCS Centro di Riferimento Oncologico della Basilicata (CROB)

Research output: Contribution to journal › Article › peer-review

Abstract

The discovery of epidermal growth factor receptor activating mutations (EGFR Mut+) has determined a paradigm shift in the treatment of non-small cell lung cancer (NSCLC). In several phase III studies, patients with NSCLC EGFR Mut+ achieved a significantly better progression-free survival when treated with a first- (gefitinib, erlotinib) or second-generation (afatinib) EGFR tyrosine kinase inhibitor (TKI) compared with standard chemotherapy. However, despite these impressive results, most patients with NSCLC EGFR Mut+ develop acquired resistance to TKIs. This review will discuss both the mechanisms of resistance to TKIs and the therapeutic strategies to overcome resistance, including emerging data on third-generation TKIs.

Original language	English
Pages (from-to)	242-250
Number of pages	9
Journal	Therapeutic Advances in Respiratory Disease
Volume	9
Issue number	5
DOIs	https://doi.org/10.1177/1753465815587820
Publication status	Published - Oct 29 2015

Keywords

AZD9291
CO-1686
epidermal growth factor receptor activating mutations
HM61713
non-small cell lung cancer
T790M mutation
tyrosine kinase inhibitors

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine
Pharmacology (medical)

Access to Document

10.1177/1753465815587820

Cite this

@article{400de03fc86d4b84956d705a3adbd1e7,

title = "Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance",

abstract = "The discovery of epidermal growth factor receptor activating mutations (EGFR Mut+) has determined a paradigm shift in the treatment of non-small cell lung cancer (NSCLC). In several phase III studies, patients with NSCLC EGFR Mut+ achieved a significantly better progression-free survival when treated with a first- (gefitinib, erlotinib) or second-generation (afatinib) EGFR tyrosine kinase inhibitor (TKI) compared with standard chemotherapy. However, despite these impressive results, most patients with NSCLC EGFR Mut+ develop acquired resistance to TKIs. This review will discuss both the mechanisms of resistance to TKIs and the therapeutic strategies to overcome resistance, including emerging data on third-generation TKIs.",

keywords = "AZD9291, CO-1686, epidermal growth factor receptor activating mutations, HM61713, non-small cell lung cancer, T790M mutation, tyrosine kinase inhibitors",

author = "Alfredo Tartarone and Rosa Lerose",

year = "2015",

month = oct,

day = "29",

doi = "10.1177/1753465815587820",

language = "English",

volume = "9",

pages = "242--250",

journal = "Therapeutic Advances in Respiratory Disease",

issn = "1753-4658",

publisher = "SAGE Publications Ltd",

number = "5",

}

TY - JOUR

T1 - Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance

AU - Tartarone, Alfredo

AU - Lerose, Rosa

PY - 2015/10/29

Y1 - 2015/10/29

N2 - The discovery of epidermal growth factor receptor activating mutations (EGFR Mut+) has determined a paradigm shift in the treatment of non-small cell lung cancer (NSCLC). In several phase III studies, patients with NSCLC EGFR Mut+ achieved a significantly better progression-free survival when treated with a first- (gefitinib, erlotinib) or second-generation (afatinib) EGFR tyrosine kinase inhibitor (TKI) compared with standard chemotherapy. However, despite these impressive results, most patients with NSCLC EGFR Mut+ develop acquired resistance to TKIs. This review will discuss both the mechanisms of resistance to TKIs and the therapeutic strategies to overcome resistance, including emerging data on third-generation TKIs.

AB - The discovery of epidermal growth factor receptor activating mutations (EGFR Mut+) has determined a paradigm shift in the treatment of non-small cell lung cancer (NSCLC). In several phase III studies, patients with NSCLC EGFR Mut+ achieved a significantly better progression-free survival when treated with a first- (gefitinib, erlotinib) or second-generation (afatinib) EGFR tyrosine kinase inhibitor (TKI) compared with standard chemotherapy. However, despite these impressive results, most patients with NSCLC EGFR Mut+ develop acquired resistance to TKIs. This review will discuss both the mechanisms of resistance to TKIs and the therapeutic strategies to overcome resistance, including emerging data on third-generation TKIs.

KW - AZD9291

KW - CO-1686

KW - epidermal growth factor receptor activating mutations

KW - HM61713

KW - non-small cell lung cancer

KW - T790M mutation

KW - tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84942568700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942568700&partnerID=8YFLogxK

U2 - 10.1177/1753465815587820

DO - 10.1177/1753465815587820

M3 - Article

C2 - 26016841

AN - SCOPUS:84942568700

VL - 9

SP - 242

EP - 250

JO - Therapeutic Advances in Respiratory Disease

JF - Therapeutic Advances in Respiratory Disease

SN - 1753-4658

IS - 5

ER -

Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this